FDA OKs Phase 2 clinical trial of KYV-101 for progressive MS
WEBJan 5, 2024 · Called KYSA-7 (NCT06138132), the open-label trial will enroll an estimated 12 patients with either primary progressive MS (PPMS) or secondary progressive MS (SPMS).
An Overview of PPMS Treatments and What's in the Pipeline
WEBRead an overview of current PPMS treatment options, current clinical studies and trials, and symptom management that has worked for one PPMS patient.
FDA approves new drug to treat multiple sclerosis | FDA
WEBOn March 28, the U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple...
Subcutaneous Ocrelizumab and Hyaluronidase Approved for RMS, PPMS
WEB5 days ago · The FDA approved ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo; Genentech), a twice-yearly subcutaneous injection, for relapsing multiple sclerosis (RMS) and primary progressive multiple ...
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze …
WEB6 days ago · ROG.SW. HALO. Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with biopharmaceutical company Halozyme Therapeutics ...
Hydroxychloroquine Shows Potential to Treat PPMS in Phase 2 …
WEBOct 8, 2021 · Treatment with hydroxychloroquine, an anti-malaria medication, appeared to help slow disability progression among people with primary-progressive multiple sclerosis (PPMS) in a small,...
Primary progressive MS confirmed as own disorder in mouse study
WEBFeb 7, 2023 · Primary progressive multiple sclerosis (PPMS) is driven by antibodies in the cerebrospinal fluid (CSF), the liquid around the brain and spinal cord — but this is not the case in the more...
Multiple Sclerosis Cure: How Close We Are and New Treatments - Healthline
WEBMay 22, 2024 · Ocrelizumab (Ocrevus): This drug treats relapsing forms of MS and primary progressive MS (PPMS). It’s the first DMT to be approved to treat PPMS and the only one approved for all four types of MS.
Beyond ocrelizumab in primary progressive multiple sclerosis
WEBSep 22, 2022 · Currently, the anti-CD20 monoclonal antibody ocrelizumab is the only approved treatment for primary progressive multiple sclerosis (PPMS).
Primary Progressive Multiple Sclerosis - Johns Hopkins Medicine
WEBWhat is primary-progressive multiple sclerosis? Multiple sclerosis (MS) is a neurodegenerative disease. It interferes with your brain's ability to control your body. It can be disabling. There are 4 main types of MS: Relapsing-remitting MS (RRMS) Primary-progressive MS (PPMS) Secondary-progressive MS (SPMS) Progressive-relapsing MS.
Skip to content